Astria Therapeutics, Inc. (NASDAQ:ATXS) Given Consensus Recommendation of “Hold” by Analysts

Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) have received an average rating of “Hold” from the ten research firms that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, six have given a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $25.00.

Several equities research analysts have commented on the company. Evercore ISI reissued an “outperform” rating and issued a $26.00 target price on shares of Astria Therapeutics in a report on Wednesday, October 1st. Wedbush set a $13.00 price target on Astria Therapeutics and gave the stock a “neutral” rating in a research note on Wednesday, October 15th. HC Wainwright cut Astria Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, October 16th. JMP Securities restated a “market perform” rating on shares of Astria Therapeutics in a research note on Wednesday, October 15th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Astria Therapeutics in a research note on Wednesday, October 8th.

Astria Therapeutics Trading Up 0.1%

Astria Therapeutics stock opened at $12.16 on Wednesday. The business’s fifty day simple moving average is $7.77 and its two-hundred day simple moving average is $6.18. Astria Therapeutics has a 12 month low of $3.56 and a 12 month high of $12.52. The company has a market capitalization of $686.25 million, a price-to-earnings ratio of -6.05 and a beta of 0.43.

Astria Therapeutics (NASDAQ:ATXS) last released its earnings results on Tuesday, August 12th. The biotechnology company reported ($0.57) EPS for the quarter, topping the consensus estimate of ($0.61) by $0.04. On average, equities research analysts predict that Astria Therapeutics will post -1.65 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Vestal Point Capital LP raised its stake in shares of Astria Therapeutics by 8.2% in the second quarter. Vestal Point Capital LP now owns 4,522,000 shares of the biotechnology company’s stock worth $24,238,000 after purchasing an additional 342,000 shares during the last quarter. JPMorgan Chase & Co. increased its position in Astria Therapeutics by 4,607.1% during the second quarter. JPMorgan Chase & Co. now owns 1,696,071 shares of the biotechnology company’s stock valued at $9,091,000 after acquiring an additional 1,660,039 shares during the last quarter. Nantahala Capital Management LLC increased its position in Astria Therapeutics by 59.7% during the second quarter. Nantahala Capital Management LLC now owns 1,069,530 shares of the biotechnology company’s stock valued at $5,733,000 after acquiring an additional 400,000 shares during the last quarter. Adage Capital Partners GP L.L.C. increased its position in Astria Therapeutics by 48.8% during the second quarter. Adage Capital Partners GP L.L.C. now owns 875,000 shares of the biotechnology company’s stock valued at $4,690,000 after acquiring an additional 286,800 shares during the last quarter. Finally, ADAR1 Capital Management LLC increased its position in Astria Therapeutics by 605.3% during the first quarter. ADAR1 Capital Management LLC now owns 641,690 shares of the biotechnology company’s stock valued at $3,427,000 after acquiring an additional 550,706 shares during the last quarter. Hedge funds and other institutional investors own 98.98% of the company’s stock.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.